摘要
在过去的10年,小分子核糖核酸已经广泛地引起科学家的注意力,因为肿瘤抑制剂或肿瘤发展过程中的致癌基因,转移以及对各种肿瘤治疗的内在抗性。小分子核糖核酸21表现出潜在的致癌功能以及几乎在所有的肿瘤中能够靶向肿瘤抑制蛋白。在细胞增殖、转移、侵略以及转移、细胞凋亡方面对小分子核糖核酸21的过度表达进行了研究。目前已经发展了不同规格、形状和成分的各种纳米级别的载体使用反义技术来抑制小分子核糖核酸的表达,来客服小分子核糖核酸的表达。小分子核糖核酸21反义寡核苷酸引用到肿瘤细胞的治疗已经是一种有潜力的治疗方案。此外,小分子核糖核酸21能够介导对放射和化学的抵抗性。本文也讨论了miR-21在人类肿瘤上扩展作用,强调了其调节靶点和机制。
关键词: 小分子核糖核酸21,肿瘤,靶向蛋白质,化学/放射抵抗性,致癌靶点
Current Gene Therapy
Title:miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Volume: 16 Issue: 6
关键词: 小分子核糖核酸21,肿瘤,靶向蛋白质,化学/放射抵抗性,致癌靶点
摘要: In the past decade, miRNAs have been extensively attracted the scientist’s attentions as tumor suppressors or oncogenes that have been implicated in tumor progression, metastasis and intrinsic resistance to various cancer therapies. microRNA-21 (miR-21) demonstrates a potential oncogenic function and targets tumor inhibitor proteins in almost all types of cancer. miR-21 overexpression has been studied in terms of cell proliferation, migration, invasion, metastasis, and apoptosis regulation. Inhibition of miRNA expression using antisense technology by various nanovectors of different sizes, shapes and compositions has been evolved progressively to overcome the barriers confronted by miRNA delivery. Application of miR-21 antisense oligonucleotides for treating cancerous cells has become a promising achievement for cancer therapy. Moreover, miR-21 can mediate resistance to radiation and chemotherapy. The expanding role of miR-21 functions in human cancers with an emphasis on its regulatory targets and mechanisms, miR-21 related achievements against cancer promotion have been discussed.
Export Options
About this article
Cite this article as:
miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance, Current Gene Therapy 2016; 16 (6) . https://dx.doi.org/10.2174/1566523217666170102105119
DOI https://dx.doi.org/10.2174/1566523217666170102105119 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date
Recent Patents on Biomarkers Oxygen Sensing, Cardiac Ischemia, HIF-1α and Some Emerging Concepts
Current Cardiology Reviews Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Anti-Cancer Agents in Medicinal Chemistry High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets An Overview of Pathogenesis and Pathophysiology in Endometriosis
Current Women`s Health Reviews Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design New Therapeutic Strategies for Castration-Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery QSAR and the Prediction of T-Cell Epitopes
Current Proteomics G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Epigenetic Alterations of the Wnt/β -Catenin Pathway in Human Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry Development of a Radiolabeled Amlodipine Analog for L-type Calcium Channel Imaging
Current Radiopharmaceuticals Electrochemical Biosensors as a Screening Tool of In Vitro DNA-Drug Interaction
Current Pharmaceutical Analysis